Background: Rheumatic heart disease (RHD), an autoimmune sequela of Group A streptococcal infection, is a chronic valvular disease affecting 32 million people worldwide, predominantly in developing nations. As the predisposition to autoimmune sequela still remains post transplantation, our primary objective was to assess if there were differences in mortality and rejection rates.
| INTRODUC TI ON
Rheumatic heart disease (RHD) is one of the leading causes of heart disease in the developing world, with an estimated prevalence of 32 million affected persons and 200 000-250 000 deaths per year. 1, 2 RHD is an autoimmune-mediated disease with a clinical spectrum of pericarditis, myocarditis, and valvulitis. 3 Valvular damage is hypothesized to result from molecular mimicry to prior group A streptococcus pharyngitis, during which the patient's own immune system responds to both Group A streptococcus (GAS) and cardiac proteins. 4 Without penicillin prophylaxis, re-exposure to GAS may boost cross-reactive CD4 + T cells and autoreactive antibody responses, resulting in progressive valvular damage and subsequent heart failure. Operative interventions include valvuloplasty or valve replacement. Heart transplantation remains the only curative intervention after other operative interventions have failed. Post transplantation, GAS re-exposure may elicit similar pre-transplantation pathology. The goal of this study was to assess if there were differences in mortality and graft survival following heart transplantation compared to non-RHD recipients.
| ME THODS
We queried the International Society for Heart and Lung Transplantation (ISHLT) adult heart transplant registry for patients who had undergone heart transplantation for RHD from 1988 to mune sequela still remains post transplantation, our primary objective was to assess if there were differences in mortality and rejection rates. 95% CI 1.09-1.82, P = 0.009) were associated with an increased odds of one-year mortality (P = 0.0013).
Methods and Results

Conclusions:
At one year post transplantation, RHD recipients had a significantly lower survival than DCM recipients. RHD status was also an independent predictor of mortality at 1 year post transplantation.
K E Y W O R D S
ISHLT, rheumatic heart disease, transplantation 2014 using the following search terms: "rheumatic," "rheumatic fever," "rheumatic heart disease," or "RHD" under the diagnosis cat- TA B L E 1 Pre-transplantation characteristics of patients with rheumatic heart disease (RHD) and controls. Controls were matched based on age ±5 years, gender and year of transplantation recipients) and were not included in the survival analyses. KaplanMeier (KM) survival curves were compared by log-rank test. We first compared variables with our primary outcome of one-year mortality via univariate analysis. Variables with P-value ≤0.2 were used to build the multivariate model using stepwise selection and goodness of fit testing. Baseline characteristics recorded prior to transplantation are detailed in Table 1 Use of induction immunosuppression was comparable between the groups (58.5% for RHD vs. 48% for the DCM, Table 2 ). Basiliximab was the most common drug used for induction (24.4% for RHD vs.
| RE SULTS
17.6% for DCM, Table 2 ). There were no significant differences between types of maintenance immunosuppression between both groups; though there was a trend toward higher cyclosporine use in the RHD group (51.2% vs. 36.8% in the control group). There was no difference in the rate of the 1st episode of rejection within the first year of transplant (RHD 10.26% vs. control 8.42%, P = 0.76).
One-year mortality in the RHD group was 17.95% vs. Table 3 ) and pre-transplant creatinine (OR 1.41, 95% CI 1.09-1.82, P = 0.009, Table 3 ) were independent predictors of death (P = 0.0013).
| D ISCUSS I ON
We present data for the largest cohort of RHD heart transplant recipients to date. As RHD is predominantly found in developing nations, 6,7 few studies have assessed outcomes for heart transplantation performed for RHD. Outcomes with heart transplantation in general are excellent.
About 4500 heart transplants are performed annually in the world with 1-year survival approaching 90% in the current era. 9 In our study, we observed a higher mortality at one year post transplantation among RHD patients compared to DCM patients, matched for age ±5 years, gender and year of transplantation. RHD was also a significant predictor of one-year mortality in our multivariate analysis. More RHD recipients used cyclosporine as part of their maintenance immunosuppression regimen than DCM recipients, though cyclosporine use was not associated with the 1-year mortality in the final multivariate model. Cyclosporine has been associated with reduced survival and more rejection compared to tacrolimus. 10, 11 The rate of the 1st episode of rejection within the first year was similar between both groups. The reason(s) underlying this increased mortality rate is unclear from our current retrospective analysis of registry data. At baseline, RHD patients had higher mean PCWP, which may be an indication of the severity of heart failure. They also had a greater percentage of cardiac surgeries (mainly valvular). However, neither factor was significant in the multivariate model. As noted from epidemiologic studies, RHD patients have circulating antibodies against GAS, some of which may be cross-reactive and boosted with recurrent infection. 12, 13 Re-exposure to GAS post-transplantation may therefore theoretically increase the likelihood for valve destruction, graft dysfunction, and survival, though we would not expect this process to occur rapidly within the first year. 14,15 Regardless, we believe that RHD recipients may benefit from continued penicillin prophylaxis in the first year following transplantation, tonsillectomy to remove a potential nidus, and minimization of exposures to GAS (e.g., close contact with children). Baseline renal dysfunction has already been described as an independent predictor of mortality in heart transplant studies, as we also found in our analysis. 16, 17 Additional cofactors contributing to the mortality difference at 1 year post transplantation would be better addressed in a prospective study.
This study has several limitations. As it is a retrospective study, Missing data for this large registry were excluded for survival curves. 
| CON CLUS ION
We conducted a large case-control analysis of RHD patients that underwent heart transplantation using an international registry and demonstrated that RHD was an independent predictor of 1-year mortality following transplantation. We were unable to elucidate the etiologic factors leading to this increased mortality from our retrospective study. We recommend that a future prospective study should include streptolysin O antibody titers (a serodiagnostic marker for prior GAS infection), history of tonsillectomy, penicillin
prophylaxis pre-and post-transplantation, and valvular pathology allowing us to interrogate potential RHD immunopathologic components. This may help us address the role of penicillin prophylaxis in RHD transplant recipients.
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